References :
1. Sharma, L., Losier, A., Tolbert, T., Dela Cruz, C.S. and Marion, C.R., 2017. Atypical pneumonia: updates on Legionella, Chlamydophila, and Mycoplasma pneumonia. Clinical Chest Medicine, 38(1), pp.45–58.
2. Yan, Y., Yang, G., Fan, X., Zhang, Y., Liu, F. and Hu, X., 2023. Immunomodulatory role of azithromycin: Potential mechanisms and clinical benefits. Frontiers in Pharmacology. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030824/
3. Lendermon, E.A., Coon, T.A., Bednash, J.S., Weathington, N.M., McDyer, J.F. and
Mallampalli, R.K., 2017. Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation. Respiratory Research, 18(1), pp.1–8.
Declaration of Conflict of Interest:
The presenting author declares no conflicts of interest related to this study. All co-authors have disclosed no potential conflicts of interest.
Funding / Sponsorship:
This study received no financial support from tobacco or tobacco-related industries. The research was conducted without external commercial sponsorship. All authors declare that there was no industry involvement influencing the study design, data collection, analysis, interpretation, or manuscript preparation.
Copyright / Ethical Statement:
The presenting author confirms that the content of this abstract is original, does not infringe upon any copyright or third-party rights, and has been approved by all co-authors.